Pemetrexed Disodium for Injection Clinical Trials
6 recruitingDrug
Phase 34Phase 22Phase 11
Showing 1–6 of 6 trials
Recruiting
Phase 2
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd230 enrolled24 locationsNCT06783647
Recruiting
Phase 1Phase 2
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.156 enrolled2 locationsNCT06474455
Recruiting
Phase 3
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Recurrent Cervical CancerMetastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.398 enrolled1 locationNCT07418749
Recruiting
Phase 3
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
NSCLC Patients With Brain Metastasis
Allist Pharmaceuticals, Inc.380 enrolled1 locationNCT06970639
Recruiting
Phase 3
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR
Allist Pharmaceuticals, Inc.300 enrolled2 locationsNCT06956001
Recruiting
Phase 3
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.402 enrolled1 locationNCT06738251